| P50 | author | Dominic C Voon | Q88023886 |
| P2093 | author name string | Rebecca A Jackson | |
| | Jean P Thiery | |
| | Ruby Y Huang | |
| P2860 | cites work | E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex | Q39861678 |
| | Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer | Q39894847 |
| | Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. | Q39916367 |
| | Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors | Q39929011 |
| | Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma | Q39966334 |
| | ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo | Q40109424 |
| | Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma | Q40125585 |
| | Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. | Q40204082 |
| | Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition | Q40360895 |
| | MicroRNA-125b attenuates epithelial-mesenchymal transitions and targets stem-like liver cancer cells through small mothers against decapentaplegic 2 and 4. | Q40962436 |
| | Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530 | Q41130127 |
| | Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features. | Q41830456 |
| | Stage-specific regulation of reprogramming to induced pluripotent stem cells by Wnt signaling and T cell factor proteins. | Q41853093 |
| | A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma | Q42113451 |
| | The complexities and caveats of lineage tracing in the mammary gland. | Q42363178 |
| | Integration of ERα-PELP1-HER2 signaling by LSD1 (KDM1A/AOF2) offers combinatorial therapeutic opportunities to circumventing hormone resistance in breast cancer | Q42669881 |
| | Vitamin C modulates TET1 function during somatic cell reprogramming | Q42708715 |
| | Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors | Q44423483 |
| | Salinomycin kills cancer stem cells by sequestering iron in lysosomes. | Q46302821 |
| | Yap-dependent reprogramming of Lgr5(+) stem cells drives intestinal regeneration and cancer | Q48071843 |
| | Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors | Q48174726 |
| | Lysine-specific demethylase 1 promotes the stemness and chemoresistance of Lgr5(+) liver cancer initiating cells by suppressing negative regulators of β-catenin signaling. | Q48198419 |
| | The Emerging Roles of RUNX Transcription Factors in Epithelial-Mesenchymal Transition | Q38744455 |
| | Replacement of Lost Lgr5-Positive Stem Cells through Plasticity of Their Enterocyte-Lineage Daughters | Q38797646 |
| | Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells | Q38868107 |
| | EMT: 2016. | Q38883448 |
| | SHP-1 is a negative regulator of epithelial-mesenchymal transition in hepatocellular carcinoma. | Q38916619 |
| | MBD3/NuRD facilitates induction of pluripotency in a context-dependent manner | Q38994364 |
| | EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis | Q38996061 |
| | TET1 exerts its tumor suppressor function by interacting with p53-EZH2 pathway in gastric cancer | Q38997619 |
| | Bright/Arid3A acts as a barrier to somatic cell reprogramming through direct regulation of Oct4, Sox2, and Nanog | Q39025517 |
| | Multimodal HDAC inhibitors with improved anticancer activity | Q39125756 |
| | Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem-cell-like state | Q39176448 |
| | MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer | Q39183436 |
| | The invasion inhibitor sarasinoside A1 reverses mesenchymal tumor transformation in an E-cadherin-independent manner. | Q39196513 |
| | Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. | Q39234744 |
| | Runx3 protects gastric epithelial cells against epithelial-mesenchymal transition-induced cellular plasticity and tumorigenicity | Q39296192 |
| | EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung | Q39488429 |
| | Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition | Q39513776 |
| | EW-7203, a novel small molecule inhibitor of transforming growth factor-β (TGF-β) type I receptor/activin receptor-like kinase-5, blocks TGF-β1-mediated epithelial-to-mesenchymal transition in mammary epithelial cells | Q39517290 |
| | HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. | Q39527047 |
| | Carcinoembryonic antigen interacts with TGF-{beta} receptor and inhibits TGF-{beta} signaling in colorectal cancers. | Q39648681 |
| | Bmi1 is essential in Twist1-induced epithelial–mesenchymal transition | Q39659307 |
| | Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer | Q39669384 |
| | The SNAG domain of Snail1 functions as a molecular hook for recruiting lysine-specific demethylase 1 | Q24306590 |
| | Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence | Q24309539 |
| | Requirement of the histone demethylase LSD1 in Snai1-mediated transcriptional repression during epithelial-mesenchymal transition | Q24324254 |
| | Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells | Q24329077 |
| | Histone demethylation mediated by the nuclear amine oxidase homolog LSD1 | Q24336747 |
| | Loss of miR-200 Inhibition of Suz12 Leads to Polycomb-Mediated Repression Required for the Formation and Maintenance of Cancer Stem Cells | Q24610880 |
| | Bmi1, stem cells, and senescence regulation | Q24614474 |
| | The epithelial-mesenchymal transition generates cells with properties of stem cells | Q24650786 |
| | SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells | Q24656966 |
| | A cell-based small molecule screening method for identifying inhibitors of epithelial-mesenchymal transition in carcinoma | Q27307150 |
| | Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 |
| | Epithelial-mesenchymal transitions in development and disease | Q27860630 |
| | Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors | Q27860937 |
| | Identification of selective inhibitors of cancer stem cells by high-throughput screening | Q28255115 |
| | Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance | Q28269714 |
| | Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer | Q28482156 |
| | A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity | Q29614209 |
| | Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition | Q29615853 |
| | Linking the p53 tumour suppressor pathway to somatic cell reprogramming | Q29616507 |
| | Suppression of induced pluripotent stem cell generation by the p53-p21 pathway | Q29619160 |
| | Generation of breast cancer stem cells through epithelial-mesenchymal transition | Q29619717 |
| | Data-Driven Discovery of Extravasation Pathway in Circulating Tumor Cells | Q31171102 |
| | A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog | Q33509682 |
| | Screening therapeutic EMT blocking agents in a three-dimensional microenvironment | Q33689694 |
| | High expression of lysine-specific demethylase 1 correlates with poor prognosis of patients with esophageal squamous cell carcinoma. | Q50926028 |
| | The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer. | Q51146366 |
| | Tet and TDG mediate DNA demethylation essential for mesenchymal-to-epithelial transition in somatic cell reprogramming. | Q53066399 |
| | Valproic acid (VPA) inhibits the epithelial-mesenchymal transition in prostate carcinoma via the dual suppression of SMAD4. | Q53410584 |
| | Fibrosis progression according to epithelial-mesenchymal transition profile: a randomized trial of everolimus versus CsA. | Q53570157 |
| | Periodic Activation of Wnt/β-Catenin Signaling Enhances Somatic Cell Reprogramming Mediated by Cell Fusion | Q60397941 |
| | Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells | Q81631602 |
| | Lineage Tracing of Mammary Stem and Progenitor Cells | Q88656065 |
| | An orally active small molecule TGF-beta receptor I antagonist inhibits the growth of metastatic murine breast cancer | Q33812340 |
| | KRAS and YAP1 converge to regulate EMT and tumor survival | Q33946244 |
| | Tgfbeta signal inhibition cooperates in the induction of iPSCs and replaces Sox2 and cMyc | Q34019451 |
| | Slug and Sox9 cooperatively determine the mammary stem cell state | Q34030957 |
| | Distinct EMT programs control normal mammary stem cells and tumour-initiating cells | Q34044818 |
| | Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. | Q34045380 |
| | A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts | Q34125363 |
| | The epigenetics of epithelial-mesenchymal plasticity in cancer | Q34310378 |
| | Stem cells and cancer; the polycomb connection | Q34341685 |
| | Phenotypic high-throughput screening elucidates target pathway in breast cancer stem cell-like cells | Q34401291 |
| | TET1 regulates hypoxia-induced epithelial-mesenchymal transition by acting as a co-activator | Q34454322 |
| | Combinatorial modulation of signaling pathways reveals cell-type-specific requirements for highly efficient and synchronous iPSC reprogramming | Q34469441 |
| | Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability | Q34516879 |
| | Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex | Q34550834 |
| | Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency | Q34771507 |
| | p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. | Q34787898 |
| | LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis | Q34935319 |
| | p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. | Q34973748 |
| | CK2 inhibitor CX-4945 blocks TGF-β1-induced epithelial-to-mesenchymal transition in A549 human lung adenocarcinoma cells | Q34984681 |
| | E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells | Q35008465 |
| | Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. | Q35076272 |
| | Protein kinase CK2α is overexpressed in colorectal cancer and modulates cell proliferation and invasion via regulating EMT-related genes | Q35094836 |
| | LSD1 overexpression is associated with poor prognosis in basal-like breast cancer, and sensitivity to PARP inhibition | Q35094931 |
| | Epithelial-to-mesenchymal transition predicts cyclosporine nephrotoxicity in renal transplant recipients | Q35108909 |
| | Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells | Q35164584 |
| | Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer | Q35258324 |
| | Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer | Q35289038 |
| | The TWIST/Mi2/NuRD protein complex and its essential role in cancer metastasis | Q35348193 |
| | Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy. | Q35640863 |
| | Axl activates autocrine transforming growth factor-β signaling in hepatocellular carcinoma | Q35669111 |
| | ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. | Q35695410 |
| | Transcriptional analysis of pluripotency reveals the Hippo pathway as a barrier to reprogramming | Q35860353 |
| | A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer | Q35883829 |
| | An epithelial marker promoter induction screen identifies histone deacetylase inhibitors to restore epithelial differentiation and abolishes anchorage independence growth in cancers | Q36110047 |
| | Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial | Q36203560 |
| | Overexpression of lysine specific demethylase 1 predicts worse prognosis in primary hepatocellular carcinoma patients | Q36450462 |
| | Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis | Q36467995 |
| | Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma | Q36557486 |
| | GRHL2-miR-200-ZEB1 maintains the epithelial status of ovarian cancer through transcriptional regulation and histone modification. | Q36591554 |
| | An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance | Q36597042 |
| | Plasticity between Epithelial and Mesenchymal States Unlinks EMT from Metastasis-Enhancing Stem Cell Capacity | Q36713524 |
| | Transcription factors interfering with dedifferentiation induce cell type-specific transcriptional profiles | Q36781956 |
| | Early epithelial phenotypic changes predict graft fibrosis | Q36796755 |
| | Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. | Q36804667 |
| | HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. | Q36932231 |
| | A combinatorial strategy for treating KRAS-mutant lung cancer | Q37080881 |
| | Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer | Q37119697 |
| | MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. | Q37156452 |
| | Dll1+ secretory progenitor cells revert to stem cells upon crypt damage | Q37211856 |
| | An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). | Q37357076 |
| | The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells | Q37452295 |
| | A new dimension in drug discovery: reversing epithelial-mesenchymal transition (EMT). | Q37465906 |
| | Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast | Q37595164 |
| | SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer | Q37595372 |
| | Src kinases as therapeutic targets for cancer | Q37604891 |
| | Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression | Q37643951 |
| | Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer | Q37665603 |
| | Current status of SRC inhibitors in solid tumor malignancies | Q37869271 |
| | Epithelial plasticity: a common theme in embryonic and cancer cells. | Q38160727 |
| | Transforming growth factor-β as a therapeutic target in hepatocellular carcinoma | Q38196739 |
| | Axl kinase as a key target for oncology: focus on small molecule inhibitors | Q38241517 |
| | MTA family of proteins in DNA damage response: mechanistic insights and potential applications | Q38261628 |
| | Systematic identification of barriers to human iPSC generation | Q38305710 |
| | Micropillar arrays as potential drug screens: Inhibition of micropillar-mediated activation of the FAK-Src-paxillin signaling pathway by the CK2 inhibitor CX-4945. | Q38422941 |
| | Reprogramming barriers and enhancers: strategies to enhance the efficiency and kinetics of induced pluripotency | Q38632891 |
| | The rationale for targeting TGF-β in chronic liver diseases. | Q38715538 |
| | TET1 promotes cisplatin-resistance via demethylating the vimentin promoter in ovarian cancer | Q38718420 |
| | Molecular features of cellular reprogramming and development | Q38736146 |
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | mutation | Q42918 |
| | epithelial to mesenchymal transition | Q74419 |
| | signal transduction | Q828130 |
| | neoplasm | Q1216998 |
| | antineoplastic resistance | Q13416904 |
| | genetic epigenesis | Q64443099 |
| | neoplastic gene expression regulation | Q66660300 |
| | cell plasticity | Q71129238 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 878-891 | |
| P577 | publication date | 2017-05-24 | |
| | 2017-07-01 | |
| P1433 | published in | Molecular Oncology | Q2190736 |
| P1476 | title | The EMT spectrum and therapeutic opportunities | |
| P478 | volume | 11 | |